News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
D2M Biotherapeutics Initiates Phase 1 Study of DM919, a Novel MICA/B Antibody for Advanced Solid Tumors, with First Patient Dosed
Friday, April 19, 2024DM Biotherapeutics Inc a clinicalstage biotech company announced today that it has initiated dosing the first patient in a phase study of DM DM is a novel monoclonal antibody targeting MICAB
Panasonic and Shinobi Therapeutics Collaborate on Cost-Effective iPS Cell Therapy Manufacturing Technology
Friday, April 19, 2024Shinobi Therapeutics a biotech firm pioneering a new line of immuneevasive iPS cell therapies has forged a collaboration with Panasonic Holdings Corp and Kyoto Universitys Center for iPS
X-Therma Receives FDA Approval for XT-Thrive® Drug Master File
Thursday, April 18, 2024XTherma Inc a pioneering biotechnology firm specializing in regenerative medicine and organ preservation has reached a significant milestone with the Food and Drug Administration accepting its Drug Master File for XTThrive This DMF encompasses the C...
Imugene and Kincell Bio Enter Strategic Partnership for Manufacturing and Process Development
Wednesday, April 17, 2024Imugene Ltd and Kincell Bio LLC have announced a strategic partnership focusing on manufacturing and process development The agreement involves Imugene selling its Current Good Manufacturing
PharmAlliance's Acquisition of CHEORS Marks a Strategic Step Forward in Pharmaceutical Expansion
Tuesday, April 16, 2024PharmAlliance a prominent pharmaceutical and life sciences services platform is thrilled to announce its latest acquisition of Complete Health Economics Outcomes Research Solutions
BioSyent Extends Agreement for RepaGyn® and Proktis-M®
Monday, April 15, 2024BioSyent Inc is excited to announce that its subsidiary BioSyent Pharma Inc has prolonged its Exclusive License and Distribution Agreement with its European partner for the RepaGyn and ProktisM products granting exclusive Canadian rights
Modalis Enters Partnership with Ginkgo Bioworks
Saturday, April 13, 2024Modalis Therapeutics Corporation has recently entered into a collaboration with Ginkgo Bioworks to join the Ginkgo Technology Network This partnership aims to provide Ginkgos global clientele in the cell and gene therapy sectors access
Candel Therapeutics Secures FDA Orphan Drug Designation for CAN-2409 Targeting Pancreatic Cancer
Friday, April 12, 2024Candel Therapeutics Inc publicly traded under the symbol CADL on the Nasdaq has been granted Orphan Drug Designation by the US Food and Drug Administration for its leading candidate
TR1X Receives FDA Approval for TRX103: Allogeneic Regulatory T-Cell Therapy Targeting Autoimmune Diseases
Thursday, April 11, 2024TrX Inc a company focusing on autoimmune and inflammatory disease treatments has received FDA approval for its Investigational New Drug application for TRX This drug aims to prevent Graft versus
Shorla Oncology Receives FDA Acceptance for New Drug Application Targeting Specific Forms of Leukemia and Other Cancers
Wednesday, April 10, 2024Shorla Oncology a specialty pharmaceutical company headquartered in both the United States and Ireland has made a significant announcement today The US Food and Drug Administration
